Dr. Agarwal’s Health Care Limited IPO Details
MAINBOARD
Dr Agarwals Health Care IPO opens for subscription on 29 Jan 2025 and closes on 31 Jan 2025. The IPO will be listed on NSE, BSE with the tentative listing date set for 04 Feb 2025.
Dr Agarwals Health Care IPO price band has been fixed at ₹382 – ₹402 per share.The face value is ₹1 per share with a lot size of 35.
Dr Agarwals Health Care IPO total issue size comprises 7,53,04,971 shares (aggregating up to ₹3027.26 Cr). This includes a fresh issue of 74,62,687 shares (aggregating up to ₹300.00 Cr). Offer for Sale consists of 6,78,42,284 shares (aggregating up to ₹2727.26 Cr). Pre-issue shareholding stands at 30,84,17,160, which will increase to 31,58,79,846 post-issue.
Dr Agarwals Health Care IPO Lot Size : Retain Minimum is 1 lot (35 shares) amounting to ₹14,070. Retain Maximum is 14 lots (490 shares) amounting to ₹196,980. SHNI Minimum is 15 lots (525 shares) amounting to ₹211,050. SHNI Maximum is 71 lots (2,485 shares) amounting to ₹998,970. BHNI Minimum is 72 lots (2,520 shares) amounting to ₹1,013,040.
The Lead Managers for Dr Agarwals Health Care IPO are crucial for the offering's success. They are responsible for a wide range of tasks, including preparing the company for the public market, managing the regulatory filings, and marketing the IPO to potential investors. The lead manager for this offering is Kotak Mahindra Capital Company Limited, Jefferies India Private Limited, Morgan Stanley India Company Pvt Ltd, Motilal Oswal Investment Advisors Limited. To assess their past performance and success in previous IPOs, you can view the Lead Manager Performance Summary report.
For detailed information, Refer to the Dr. Agarwal’s Health Care Limited RHP.
Dr Agarwals Health Care IPO Details
Dr Agarwals Health Care IPO Subscription
Dr Agarwals Health Care IPO Application Wise Breakup (Approx)
Dr Agarwals Health Care IPO Dates
- 29 Jan 2025Opening dateOPD
- 31 Jan 2025Closing dateCOD
- 01 Feb 2025Basis of AllotmentBOA
- 03 Feb 2025Initiation of RefundsIOR
- 03 Feb 2025Credit of SharesCOS
- 04 Feb 2025Listing dateLID
Dr Agarwals Health Care IPO Lot Size
Application | Lots | Shares | Amount |
---|---|---|---|
Retain Minimum | 1 | 35 | ₹14,070 |
Retain Maximum | 14 | 490 | ₹196,980 |
SHNI Minimum | 15 | 525 | ₹211,050 |
SHNI Maximum | 71 | 2485 | ₹998,970 |
BHNI Minimum | 72 | 2520 | ₹1,013,040 |
Dr Agarwals Health Care IPO Reservation
Promoter Holding
Dr Agarwals Health Care IPO Valuations
Dr Agarwals Health Care Financial Information
Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 | ||||||||||||||||||||||||||||||||||||
Assets | 3,393.41 | 2,752.82 | 1,825.17 | 1,026.13 | ||||||||||||||||||||||||||||||||||||
Revenue | 837.94 | 1,376.45 | 1,031.49 | 713.78 | ||||||||||||||||||||||||||||||||||||
Profit After Tax | 39.56 | 95.05 | 103.23 | 43.16 | ||||||||||||||||||||||||||||||||||||
Net Worth | 1,502.67 | 1,337.68 | 627.83 | 212.34 | ||||||||||||||||||||||||||||||||||||
Reserves and Surplus | 1,509.11 | 1,365.86 | 652.63 | 236.27 | ||||||||||||||||||||||||||||||||||||
Total Borrowing | 373.68 | 387.79 | 356.18 | 290.18 | ||||||||||||||||||||||||||||||||||||
Amount in ₹ Crore |
About Dr Agarwals Health Care IPO
Incorporated in 2010, Dr. Agarwal's Health Care Limited offers a comprehensive range of eye care services, including cataract and refractive surgeries, consultations, diagnoses, non-surgical treatments, and the sale of optical products, contact lenses, accessories, and eye care-related pharmaceutical items.
As of September 30, 2024, there were 737 doctors providing care to patients across the company's facilities. During this period, the company served 2.13 million patients and performed 220,523 surgeries. In the six months leading up to September 30, 2024, they served 1.15 million patients and conducted 140,787 surgeries.
The Services provided by the company are:-
Cataract surgeries Offer cataract surgical treatments at its Facilities, such as small incision cataract surgery, phacoemulsification, robotic cataract surgery and glued intraocular lens treatments;
Refractive surgeries: Refractive surgeries are procedures that correct eye refractive errors, helping individuals reduce or eliminate their need for glasses and contact lenses. The main types include LASIK, SMILE, implantable collamer lenses, and photorefractive keratectomy (PRK).
Other surgeries: Offer a range of other surgical treatments for eye ailments, such as surgical retinal treatments, corneal transplantation and pinhole pupilloplasty, oculoplasty and surgeries for the treatment of glaucoma and pterygium.
As of September 30, 2024, the company's Indian network has 28 hubs (Tertiary Facilities, including three COEs) and 165 spokes (53 Primary and 112 Secondary Facilities).
As of September 30, 2024, the company has a presence in India across 117 metro and non-metro cities spanning 14 states and four union territories through 193 Facilities.
Competitive Strength
- Largest eye care services provider in India with a trusted brand
- End-to-end, comprehensive eye care services offering
- Scalable, asset-light, hub-and-spoke operating model
- Proven clinical excellence is driven by a strong clinical board and a history of surgical innovations.
- Doctor-promoters leading a team of qualified medical professionals and supported by experienced management
- Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability
Strength Of Dr Agarwals Health Care IPO
1. Largest eyecare services provider in India with a trusted brand.
2. End-to-end, comprehensive eyecare services offering.
3. Scalable, asset-light, hub-and-spoke operating model.
4. Proven clinical excellence driven by a strong clinical board and history of surgical innovations.
5. Doctor-promoters leading a team of qualified medical professionals and supported by an experienced management.
6. Proven track record of delivering organic growth, integrating and scaling acquisitions and improving operating profitability.
Risk Of Dr Agarwals Health Care IPO
1. The company engage doctors through retainership arrangements and there is no assurance that its doctors will not prematurely terminate their arrangements with it. If the company is not able to attract and retain its doctors and other medical professionals, the company business, financial condition, results of operations and cash flows may be adversely affected.
2. The company business depends on the strength of the company brand equity and reputation. Failures to maintain and enhance its brand equity and reputation, including due to negative publicity, may adversely affect its business, reputation, financial condition, results of operations and prospects.
3. The company operates in a regulated industry, and its failures to comply with applicable safety, health, environmental, labor and other regulations, or to obtain or renew approvals, may adversely affect its business, reputation, financial condition, results of operations and cash flows.
4. A significant majority of its Facilities are located in the states of Tamil Nadu (in particular, Chennai), Maharashtra and Karnataka in India and any adverse developments in relation to these Facilities could adversely affect its business, financial condition, results of operations and cash flows.
5. The company is exposed to legal claims and regulatory actions arising from the provision of healthcare services and may be subject to liabilities arising from claims of malpractice and medical negligence which could adversely affect its business, financial condition, results of operations, cash flows, reputation and prospects.
6. Its international operations expose it to management, legal, tax, political and economic risks, and its failure to address such risks could adversely affect the company business, results of operations, financial condition and cash flows.
7. Its hub-and-spoke model may not be successful and the company may not be able to expand into new geographic regions, which could adversely affect its business, financial condition and results of operations.
8. The company has pursued and will likely continue to pursue strategic acquisitions for inorganic growth. Its inability to successfully identify, acquire and integrate suitable opportunities on commercially reasonable terms in the future could adversely affect its business, financial condition, cash flows and results of operations.
9. Its historical performance is not indicative of the company future growth or financial results and if its fail to manage the company growth or implement its growth strategies, the company business, financial condition and results of operations may be adversely affected.
10. The company is exposed to credit risks in respect of payments from third parties including under central and state government schemes, government corporations, insurance companies and third party administrators. If the company does not receive payments on a timely basis, its business, financial condition, results of operations, cash flows and prospects may be adversely affected.
Objectives Dr Agarwals Health Care IPO
- Repayment/prepayment, in part or full, of certain of the borrowings and
- General corporate purposes and unidentified inorganic acquisition.
Company Contact Details
Dr. Agarwal Health Care Limited
1 st Floor, Buhari Towers
No.4, Moores Road, Off Greams Road,
Near Asan Memorial School, Chennai 600 006
Phone: +91 44 4378 7777
Email: secretarial@dragarwal.com
Website: https://dragarwals.co.in/
Registrar Contact Details
Lead Mangers
Lead Manager Reports
Read more about Shringar House of Mangalsutra IPO
- Dr. Agarwal’s Health Care Limited IPO Detail
- Dr. Agarwal’s Health Care Limited IPO Subscription Detail
- Dr. Agarwal’s Health Care Limited IPO GMP Detail
- Checked Live Dr. Agarwal’s Health Care Limited IPO Allotment Status
- Dr. Agarwal’s Health Care Limited IPO Basis Of Allotment
- Dr. Agarwal’s Health Care Limited IPO Price Calculator
- Dr. Agarwal’s Health Care Limited IPO Stock Price